Published: 2019-09-23

Association between C reactive protein and obesity: a study in a tertiary care hospital

Lavanya Mandli


Background: Obesity and dyslipidemia, especially in children and adolescents coupled with impaired blood glucose metabolism and elevated blood pressure may result in atherosclerosis in the older ages. This study was conducted to assess the association between high levels of CRP with obesity.

Methods: Details including height and weight for BMI and serum for C reactive protein estimation was collected for all 134 patients.

Results: 60.4% were females and 49.6% were males. Among the obese patients, clinically raised CRP levels was observed in 29.2% and elevated CRP levels in 45.8% levels, while in overweight patients, 21.4% had clinically raised CRP and 46.4% has elevated CRP levels. In normal BMI patients, elevated CRP was seen in 22% and clinically raised in 1.9%.

Conclusion: Detection of CRP levels in overweight and obese patients is imperative in the early stages itself to prevent cardiovascular diseases.


Body Mass Index, Cardiovascular disease, C reactive protein, Obesity, Overweight

Full Text:



Wang Y, Lobstein T. Worldwide trends in childhood overweight and obesity. Int J Pediatr Obes. 2006;1(1):11-25.

Namburi RP, Ponnala AR, Karthik TS, Rani PR, Maheshwari R. A study on metabolic variables and its association with high sensitive C-reactive protein in obese children and adolescents. Indian J Endocr Metab. 2013;17(1):S360-2.

Flier JS. The adipocyte: storage depot or node on the energy information superhighway? Cell.1995;80(1):15-8.

Mohamed-Ali V, Pinkney JH, Coppack SW. Adipose tissue as an endocrine and paracrine organ. Int J Obes Relat Metab Disord.1998;22(12):1145-58.

Purohit A, Ghilchik MW, Duncan L, Wang DY, Singh A, Walker MM, et al. Aromatase activity and interleukin-6 production by normal and malignant breast tissues. J Clin Endocrinol Metab. 1995;80(10):3052-8.

Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-α, in vivo. J Clin Endocrinol Metab. 1997;82(12):4196-200.

Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6. J Clin Endocrinol Metab. 1998;83(3):847-50.

Banks RE, Forbes MA, Storr M, Higginson J, Thompson D, Raynes J, et al. The acute phase response in patients receiving subcutaneous IL-6. Clin Exp Immunol.1995;102(1):217-23.

Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med.1998;128(2):127-37.

Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Yudkin JS, Nijpels G, et al. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arterioscler Thromb Vasc Biol. 1999 Dec;19(12):3071-8.

Ridker PM. Inflammation, infection, and cardiovascular risk: how good is the clinical evidence? Circulation. 1998;97(17):1671-4.

Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002 Nov 14;347(20):1557-65.

Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985 Dec 19;313(25):1557-63.

Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the Am Heart Assoc. Circulation. 2003;107:499-511.

Myers GL, Rifai N, Tracy RP, Roberts WL, Alexander RW, Biasucci LM, et al. (2004) CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the laboratory science discussion group. Circulation. 2004 Dec 21;110(25):e545-9.

Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003 Jan 28;107(3):363-9.

World Health Organization Expert Committee. Physical status: the use and interpretation of anthropometry. WHO Technical Report Series No 854 1995 World Health Organization: Geneva:

Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998 Aug 25;98(8):731-3.

Koenig W, Sund M, Fröhlich M, Fischer HG, Löwel H, Döring A, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men. Circulation.1999;99(2):237-42.

Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C-reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ. 1996;312(7038):1061-5.

Ridker PM, Cushman M, Stampfer MJ, Tracey RP, Hennekens CH. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336(14):973-9.

Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282(22):2131-5.

Yudkin JS, Stehouwer C, Emeis J, Coppack S. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol. 1999;19(4):972-8.

Tchernof A, Nolan A, Sites CK, Ades PA, Poehlman ET. Weight loss reduces C- Reactive Protein Levels in Obese Menopausal Women. Circulation. 2002 Feb 5;105(5):564-9.

Lemieux I, Pascot A, Prud’homme D, Alméras N, Bogaty P, Nadeau A, et al. Elevated C-Reactive protein: another component of the atherothrombotic profile of abdominal obesity. Circulation. 2001 Jun;21(6):961-7.

Ladwig KH, Marten-Mittag B, Löwel H, Döring A, Koenig W. Influence of depressive mood on the association of CRP and obesity in 3205 middle aged healthy men. Brain Behav Immun. 2003 Aug;17(4):268-75.

Meyer AA, Kundt G, Steiner M, Schuff-Werner P, Kienast W. Impaired flow-mediated vasodilation, carotid artery intima-media thickening, and elevated endothelial plasma markers in obese children: The impact of cardiovascular risk factors. Pediatr. 2006;117(5):1560-7.

Kapiotis S, Holzer G, Schaller G, Haumer M, Widhalm H, Weghuber D, et al. A proinflammatory state is detectable in obese children and is accompanied by functional and morphological vascular changes. Arterioscler Thromb Vasc Biol. 2006;26(11):2541-6.

Peraldi P, Spiegelman B. TNF-alpha, and insulin resistance: summary and future prospects. Mol Cell Biochem. 1998;182(1-2):169-75.

Saijo Y, kiyota N, Kawasaki Y, Miyazaki Y, Kashimura J, Fukuda M, et al. Relationship between C-reactive protein and visceral adipose tissue in healthy Japanese subjects. Diabetes Obes Metab. 2004 Jul;6(4):249-58.

Sutin AR, Stephan Y, Luchetti M, Terracciano A. Perceived weight discrimination and C‐reactive protein. Obesity. 2014 Sep;22(9):1959-61.